Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CanSino Biologics, Inc. Class H ( (HK:6185) ) has shared an announcement.
CanSino Biologics Inc. has announced the convening of its 2025 first extraordinary general meeting to discuss several key resolutions, including the adoption of the 2025 A Share Incentive Scheme and H Share Option Scheme. These initiatives are aimed at enhancing the company’s operational framework and incentivizing key personnel, which could potentially strengthen its market position and align stakeholders’ interests with the company’s growth objectives.
The most recent analyst rating on (HK:6185) stock is a Buy with a HK$66.60 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in China, primarily focused on the development and production of vaccines. The company operates in the biopharmaceutical industry and is known for its innovative approaches to vaccine development, targeting various infectious diseases.
Average Trading Volume: 2,314,314
Technical Sentiment Signal: Buy
Current Market Cap: HK$15.24B
Learn more about 6185 stock on TipRanks’ Stock Analysis page.